Skip to content

Mesacup Test MPO, Model 11053

by Rhigene, Inc.

510(k) K040586

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 6 Oct 2026. What this means

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK040586 Date22 Mar 2004ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 6 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
MOB
Device Class
Class II
Regulation
21 CFR Part 866.5660
Advisory Committee
Immunology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Mesacup Test MPO, Model 11053, is a semi-quantitative enzyme-linked immunosorbent assay (ELISA) designed for the detection of IgG anti-myeloperoxidase (MPO) antibodies in human serum. It falls under the classification of a Test System for Antineutrophil Cytoplasmic Antibodies (ANCA) and is used within the field of immunology to aid in diagnostic evaluations.

This device is supplied as a single-use diagnostic test kit and is intended for use in clinical laboratory settings. It is regulated under FDA 510(k) clearance (K040586) with a classification as a Class II device under regulation 866.5660. The test requires proper storage and handling as specified in the accompanying instructions to ensure accurate results.

Other devices from Rhigene, Inc.

See all devices from Rhigene, Inc. →

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What clinical specialty is the Mesacup Test MPO, Model 11053, primarily used in, and how does it assist in patient evaluation?

    The Mesacup Test MPO, Model 11053, is designed for use in immunology, specifically to detect IgG anti-myeloperoxidase (MPO) antibodies in human serum. These antibodies are associated with certain autoimmune conditions, such as vasculitis, helping clinicians refine diagnostic evaluations in patients suspected of having ANCA-related diseases. The semi-quantitative ELISA format provides measurable results to aid in differential diagnosis.

  • Is the Mesacup Test MPO, Model 11053, intended for in-office use or must it be performed in a clinical laboratory setting?

    The device is explicitly intended for use in clinical laboratory settings only, not for point-of-care or in-office testing. This is due to its classification as a diagnostic test system requiring controlled conditions, proper handling, and adherence to laboratory protocols to ensure accurate and reliable results.

  • How is the Mesacup Test MPO, Model 11053, supplied, and is it reusable or single-use?

    The Mesacup Test MPO, Model 11053, is supplied as a single-use diagnostic test kit. Each kit is designed for one test cycle, ensuring sterility and consistency of results. Reuse is not recommended or supported by the manufacturer, as it could compromise accuracy or introduce contamination.

  • What regulatory pathway was followed for FDA clearance of the Mesacup Test MPO, Model 11053, and what does this mean for its use?

    The device underwent a traditional 510(k) clearance process through the FDA, classified as substantially equivalent (SESE) under regulation 866.5660 and reviewed by the Immunology (IM) Advisory Committee. This means the manufacturer demonstrated that the device is as safe and effective as a legally marketed predicate device, allowing its use in clinical settings for the intended purpose of detecting IgG anti-MPO antibodies in human serum.